Navigation Links
BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Date:9/19/2013

LYNBROOK, N.Y., Sept. 19, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Aegis Capital 2013 Healthcare Conference.

The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m. EDT (1:00 p.m. PDT) at the Encore at Wynn hotel in Las Vegas, NV. This event will not be webcast.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada, Mexico, Brazil and Australia. CCH is in clinical development for the treatment of several additional promising indications. The PDUFA date for XIAFLEX for Peyronie's disease is December 6, 2013. Auxilium is also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects to initiate a Phase II trial of CCH for cellulite in the third quarter of this year and next stage trials of CCH for frozen shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase II trials. BioSpecifics expects top-line data from these trials in the second half of the year. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
4. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
5. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
8. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
9. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
11. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... today announced an exhibitor sponsorship at MobileIron Live! 2017 in Santa ... technologies for an immersive, educational approach to helping organizations maximize the benefits of ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... outcomes, today released the podcast, “Make Plans for MACRA,” highlighting the ... into the physician's office and how physicians and other clinicians are reimbursed for ...
(Date:4/26/2017)... ... 2017 , ... CareSet Labs today is releasing an important ... Part D Medicare data. The dataset, called PaPR (Providers and Prescribing Records) details ... paper. The PaPR (pronounced "paper") data set aggregates this information on a ...
Breaking Medicine News(10 mins):